- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04282668
A Study of TAS1440 With ATRA in Subjects With r/r AML
May 2, 2024 updated by: Astex Pharmaceuticals, Inc.
A Phase 1 Study of Safety, Pharmacokinetics, and Preliminary Activity of TAS1440, as a Single Agent and in Combination With All-Trans Retinoic Acid (ATRA) in Subjects With Relapsed or Refractory (r/r) Acute Myeloid Leukemia (AML)
This is a multicenter, 2-part, Phase 1 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of TAS1440 administered as a single agent and in combination with all-trans retinoic acid (ATRA) in participants with acute myeloid leukemia (AML) who have relapsed or are refractory (r/r) to prior treatment.
The study duration is expected to be approximately 30 months.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85719
- University of Arizona Cancer Center Site#127
-
-
Kentucky
-
Louisville, Kentucky, United States, 40207
- Norton Cancer Institute Site# 108
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Medical School Site#107
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University Site#111
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center Site#112
-
-
Texas
-
Dallas, Texas, United States, 75246
- Baylor Scott & White Research Institute Site#110
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center Site#101
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutchinson Cancer Research Center Site#105
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Have a projected life expectancy of at least 12 weeks and be in stable condition to complete 1 full cycle (4 weeks) of treatment.
- Have histological confirmation of AML by World Health Organization (WHO) 2016 criteria and who have failed all other available conventional therapies.
- Have a peripheral blood or bone marrow blast count >5% at the time of enrollment.
Have disease that:
- is refractory to standard induction chemotherapy, including but not limited to anthracycline and cytarabine combination therapy, or
- has relapsed after anthracycline and cytarabine therapy or stem cell transplant (SCT), or
- is refractory to or has relapsed after a front-line regimen containing a hypomethylating agent, alone or in combination.
- Have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 1.
- Have adequate renal function as demonstrated by a serum creatinine ≤1.5 × upper limit of normal (ULN) or calculated creatinine clearance (by the standard Cockcroft-Gault formula) of ≥60 mL/min.
Have adequate liver function as demonstrated by the following:
- aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3 × upper limit of normal (ULN)
- AST and ALT <5 × ULN (if considered due to leukemic organ involvement).
- Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.
Exclusion Criteria:
- Known clinically active central nervous system leukemia.
- BCR-ABL-positive leukemia.
- Diagnosis of acute promyelocytic leukemia (M3 AML or APML or APL).
- Second malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy.
Grade 3 or higher graft versus host disease (GVHD), or GVHD requiring treatment with either:
- a calcineurin inhibitor, or
- prednisone more than 5 mg/day (Note: Prednisone at any dose for other indications is allowed).
- Total serum bilirubin ≥1.5 × ULN (except for subjects with Gilbert's Syndrome for whom direct bilirubin is >2.5 × ULN), or liver cirrhosis, or chronic liver disease Child-Pugh Class B or C.
- Known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer being treated with antivirals is allowed. For subjects considered at risk of viral exposure, serologies should be used to establish negativity.
- Known significant mental illness or other condition such as active alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the subject to high risk of non-compliance with the protocol.
- Myocardial impairment of any cause (eg, cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, or congestive heart failure) resulting in heart failure by New York Heart Association (NYHA) Criteria (Class III or IV staging).
- Screening 12-lead echocardiogram with measurable QTc interval (according to either Fridericia's or Bazett's correction) of >480 milliseconds.
- Active, uncontrolled infection. Participants with an infection receiving treatment (antibiotic, antifungal, or antiviral treatment) must be afebrile and hemodynamically stable for ≥72 hours before enrollment.
- Non-AML-associated pulmonary disease requiring >2 liters per minute (LPM) oxygen.
- Proliferative AML with total white blood cells > 20,000/uL
- Any other condition that puts the participant at an imminent risk of death.
- Treated with any investigational therapy within 2 weeks of the first dose of study treatment.
- Inability to swallow oral medication.
- Known hypersensitivity to ATRA, any of its components, or other retinoids.
- Known sensitivity to parabens.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TAS1440
TAS1440 as a single agent administered once daily (QD) on specific days during each 28-day cycle in Part 1.
|
Form: Capsule or Tablet Route of Administration: Oral
|
Experimental: TAS1440 + ATRA
TAS1440 administered QD on specific days during each 28-day cycle in combination with ATRA twice daily (BID) in Part 2.
|
Form: Capsule or Tablet Route of Administration: Oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety: Number of participants with treatment-emergent adverse events (TEAEs)
Time Frame: Approximately 30 months
|
Approximately 30 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Response rate: Number of participants with complete remission (CR), complete remission with incomplete blood count recovery (CRi), partial remission (PR) and complete remission with partial hematological recovery (CRh)
Time Frame: Approximately 30 months
|
Approximately 30 months
|
Overall survival: Time from the date of the first dose until death due to any cause
Time Frame: Approximately 30 months
|
Approximately 30 months
|
Pharmacokinetic parameter: Area under the curve (AUC)
Time Frame: Up to Day 8 of Cycle 1 and Cycle 2 (28 days per cycle)
|
Up to Day 8 of Cycle 1 and Cycle 2 (28 days per cycle)
|
Pharmacokinetic parameter: Maximum plasma concentration (Cmax)
Time Frame: Up to Day 8 of Cycle 1 and Cycle 2 (28 days per cycle)
|
Up to Day 8 of Cycle 1 and Cycle 2 (28 days per cycle)
|
Pharmacokinetic parameter: Minimum plasma concentration (Cmin)
Time Frame: Up to Day 8 of Cycle 1 and Cycle 2 (28 days per cycle)
|
Up to Day 8 of Cycle 1 and Cycle 2 (28 days per cycle)
|
Pharmacokinetic parameter: Time to reach maximum plasma concentration (Tmax)
Time Frame: Up to Day 8 of Cycle 1 and Cycle 2 (28 days per cycle)
|
Up to Day 8 of Cycle 1 and Cycle 2 (28 days per cycle)
|
Pharmacokinetic parameter: Half-life (t1/2)
Time Frame: Up to Day 8 of Cycle 1 and Cycle 2 (28 days per cycle)
|
Up to Day 8 of Cycle 1 and Cycle 2 (28 days per cycle)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 15, 2020
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
February 21, 2020
First Submitted That Met QC Criteria
February 21, 2020
First Posted (Actual)
February 25, 2020
Study Record Updates
Last Update Posted (Estimated)
May 3, 2024
Last Update Submitted That Met QC Criteria
May 2, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAS1440-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States